Guggenheim Maintains Buy on InflaRx, Lowers Price Target to $14
Benzinga Newsdesk 7 months ago
NewsPrice TargetAnalyst Ratings
Guggenheim analyst Yatin Suneja maintains InflaRx (NASDAQ:IFRX) with a Buy and lowers the price target from $22 to $14.
Guggenheim analyst Yatin Suneja maintains InflaRx (NASDAQ:IFRX) with a Buy and lowers the price target from $22 to $14.